Cetamolol: a new cardioselective beta-adrenoceptor blocking agent without membrane-stabilizing activity.

Area of Science:

• Pharmacology
• Cardiovascular Medicine
• Drug Discovery

Background:

• Cetamolol is a novel beta-adrenoceptor blocker with partial agonist activity and cardioselectivity.
• Membrane-stabilizing activity is a key property of some beta-blockers, influencing their therapeutic profile.
• Comparative studies are essential to understand the unique pharmacological properties of new drug candidates.

Purpose of the Study:

• To investigate the in vivo membrane-stabilizing effects of cetamolol.
• To compare cetamolol's membrane-stabilizing activity with established beta-blockers and local anesthetics.
• To elucidate the pharmacological profile of cetamolol, particularly its lack of membrane stabilization.

Main Methods:

• In vivo studies in animal models (rabbits, dogs, rats).
• Assessment of local anesthetic effects on rabbit cornea and rat tail motor nerve.
• Evaluation of antiarrhythmic efficacy against induced ventricular arrhythmias and tachycardia.
• Measurement of cardiac automaticity and atrioventricular conduction time.
• Dose-response assessment of cardiac contractility.

Main Results:

• Cetamolol did not induce local anesthesia in the rabbit cornea or rat tail nerve.
• It was ineffective in reversing coronary artery ligation-induced ventricular arrhythmias in dogs.
• Cetamolol failed to reduce cardiac automaticity in catecholamine-depleted dogs.
• No significant increase in atrioventricular conduction time was observed in vagotomized/atropinized dogs, suggesting a lack of direct membrane stabilization.
• Cetamolol restored sinus rhythm in ouabain-induced ventricular tachycardia and showed a dose-dependent decrease in cardiac contractility after an initial increase due to intrinsic sympathomimetic activity.

Conclusions:

• Cetamolol lacks membrane-stabilizing activity, even at high doses.
• Its pharmacological effects are primarily mediated through mechanisms other than membrane stabilization.
• These findings differentiate cetamolol from other beta-adrenergic blockers with known membrane-stabilizing properties.